Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan Plus Exercise in Peripheral Artery Disease
NCT02593110Completed
- Sponsor
- Northwestern University
- Start
- Jan 2016
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of telmisartan in peripheral artery disease (PAD) (4 arms), sponsored by Northwestern University. Primary endpoint: Six-minute Walk Performance at 6 months. Started Jan 2016; status: completed.
02
Drugs
telmisartan
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT02593110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593110.